Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 10:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 2,162 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: placebo pills Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Prevention of Menstrual Migraines: Using Frovatriptan or Placebo During Hormone Free Intervals

NCT00700128
View directory record Official record
Conditions
Migraines, Bleeding, Spotting
Interventions
frovatriptan, placebo
Drug
Lead sponsor
Scott and White Hospital & Clinic
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Temple, Texas
Source: ClinicalTrials.gov public record
Updated Jul 25, 2011 · Synced Oct 7, 2026, 10:46 AM EDT
Completed Phase 2 Interventional

An Efficacy and Safety Study of XP19986 in Subjects With Symptomatic GERD

NCT00557401
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
XP19986 SR3, 20 mg QD, XP19986 SR3, 40 mg QD, XP19986 SR3, 60 mg QD, XP19986 SR3, 30 mg BID, Placebo
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 7, 2026, 10:46 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy and Mechanisms of Naltrexone+Bupropion for Binge Eating Disorder

NCT03539900
View directory record Official record
Conditions
Binge-Eating Disorder
Interventions
Bupropion Hydrochloride, Naltrexone Hydrochoride Drug Combination, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Oct 7, 2026, 10:46 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Trial of CF101 to Treat Patients With Psoriasis

NCT01265667
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
CF101, Placebo
Drug
Lead sponsor
Can-Fite BioPharma
Industry
Eligibility
18 Years to 80 Years
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Oct 7, 2026, 10:46 AM EDT
Completed Phase 1 Interventional

Examining Caffeine as a Treatment for Antidepressant-induced Arousal Dysfunction in Women

NCT05685407
View directory record Official record
Conditions
Female Sexual Arousal Disorder
Interventions
Caffeine, Placebo
Drug · Other
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 7, 2026, 10:46 AM EDT
Completed Not applicable Interventional

Delivering Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention in Opioid Use Disorder

NCT05053503
View directory record Official record
Conditions
Opioid-use Disorder, Opioid Withdrawal
Interventions
Sparrow Ascent Therapy System, Lofexidine, Extended-release injectable naltrexone
Device · Drug
Lead sponsor
Spark Biomedical, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
4
States / cities
Rancho Mirage, California • Crownsville, Maryland • Center City, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2025 · Synced Oct 7, 2026, 10:46 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Modulation of Micro-RNA Pathways by Gemfibrozil in Predementia Alzheimer Disease

NCT02045056
View directory record Official record
Conditions
Preclinical Alzheimer's Disease
Interventions
Gemfibrozil, Placebo
Drug
Lead sponsor
Gregory Jicha, 323-5550
Other
Eligibility
65 Years to 90 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Oct 7, 2026, 10:46 AM EDT
Completed Phase 1 Interventional

An ACE Inhibitor (Perindopril) or an Angiotensin Receptor Blocker (Candesartan) as a Treatment for Methamphetamine Dependence

NCT01062451
View directory record Official record
Conditions
Methamphetamine Dependence, Methamphetamine Abuse, Substance Abuse
Interventions
Perindopril, Placebo, Candesartan
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 26, 2022 · Synced Oct 7, 2026, 10:46 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Trial of the Treatment of Chronic Laryngitis With Amitryptiline

NCT02434523
View directory record Official record
Conditions
Laryngeal Diseases, Chronic Laryngeal Neuropathy
Interventions
Amitriptyline, Placebo
Drug · Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 64 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Oct 7, 2026, 10:46 AM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia

NCT00158223
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders
Interventions
Pimozide, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
3
States / cities
New York, New York • W. Brentwood, New York
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced Oct 7, 2026, 10:46 AM EDT
Completed Phase 4 Interventional Results available

A Multi-Risk Factor Strategy vs a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensives at Extra Risk

NCT00412113
View directory record Official record
Conditions
Dyslipidemia, Hypertension
Interventions
Amlodipine besylate, Amlodipine besylate/atorvastatin calcium single pill combination
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
21 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
51
States / cities
Birmingham, Alabama • Mesa, Arizona • Garden Grove, California + 44 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Oct 7, 2026, 10:46 AM EDT
Recruiting Phase 2 Interventional

Prevention/Reduction of ASRs and PTSD to Sustain Civilian Performance With Sublingual Cyclobenzaprine HCl (TNX-102 SL)

NCT06636786
View directory record Official record
Conditions
Acute Stress Reaction, Acute Stress Disorder, Neurocognitive Function, Post-traumatic Stress
Interventions
Cyclobenzaprine HCl, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 55 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
9
States / cities
Birmingham, Alabama • Indianapolis, Indiana • Kansas City, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 7, 2026, 10:46 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Cognition With Neurodegradation Countermeasure

NCT05715073
View directory record Official record
Conditions
Hemodynamics, Caffeine, TeaCrine, Cognitive Change
Interventions
TeaCrine and Caffeine, Caffeine, Placebo
Dietary Supplement · Other
Lead sponsor
University of South Carolina
Other
Eligibility
18 Years to 45 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Oct 7, 2026, 10:46 AM EDT
Withdrawn Phase 2 Interventional

Growth Hormone Secretagogue MK-0677's Effect on Lean Body Mass in Chronic Kidney Disease Stage 4/5 Subjects

NCT01343641
View directory record Official record
Conditions
Chronic Kidney Disease, Kidney Disease
Interventions
MK-0677, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Oct 7, 2026, 10:46 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Lipidomics Screening of Celecoxib in ex Vivo Human Whole Blood Assay - Part B

NCT02413203
View directory record Official record
Conditions
Healthy
Interventions
Celecoxib, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 7, 2026, 10:46 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Double Blind Trial of Duloxetine in Chronic Fatigue Syndrome

NCT00375973
View directory record Official record
Conditions
Fatigue Syndrome, Chronic
Interventions
Duloxetine, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 21, 2015 · Synced Oct 7, 2026, 10:46 AM EDT
Recruiting Phase 2 Interventional

Colchicine to Reduce Your SympToms And Lower Levels of Inflammation, Zeroing in on Effective CPPD Disease Treatment

NCT06855433
View directory record Official record
Conditions
CPPD - Calcium Pyrophosphate Deposition Disease
Interventions
Colchicine Pill, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
5
States / cities
Birmingham, Alabama • Los Angeles, California • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 7, 2026, 10:46 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Clinical Trial Evaluating the Efficacy of AGB101 for Reducing Hippocampal Overactivity in Older Adults

NCT06919926
View directory record Official record
Conditions
Hippocampal Overactivity, Dementia
Interventions
AGB101, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 7, 2026, 10:46 AM EDT
Withdrawn Not applicable Interventional

Hydrocortisone for Prevention of Post-Traumatic Stress Disorder

NCT02402114
View directory record Official record
Conditions
Post-Traumatic Stress Disorder
Interventions
Hydrocortisone
Drug
Lead sponsor
Albert Einstein Healthcare Network
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 7, 2026, 10:46 AM EDT
Completed Phase 1Phase 2 Interventional Results available

S-Equol in Alzheimer's Disease 2 Trial

NCT03101085
View directory record Official record
Conditions
Alzheimer Disease
Interventions
S-equol and Placebo, Placebo and S-equol
Drug
Lead sponsor
Russell Swerdlow
Other
Eligibility
50 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Fairway, Kansas • Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 25, 2024 · Synced Oct 7, 2026, 10:46 AM EDT
Completed Phase 3 Interventional Results available

Extended Varenicline Treatment for Smoking Among Cancer Patients

NCT01756885
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Varenicline, Placebo, Smoking Cessation Counseling
Drug · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Chicago, Illinois • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Oct 7, 2026, 10:46 AM EDT
Completed Phase 2 Interventional

Efficacy of Pregnenolone in Patients With Schizophrenia

NCT00615511
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
placebo pregnenolone, pregnenolone
Dietary Supplement
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
3
States / cities
Piscataway, New Jersey • New York, New York • White Plains, New York
Source: ClinicalTrials.gov public record
Updated Dec 21, 2015 · Synced Oct 7, 2026, 10:46 AM EDT
Completed Phase 2 Interventional

Effectiveness of Amantadine and Propranolol for Treating Cocaine Dependence - 2

NCT00158132
View directory record Official record
Conditions
Cocaine-Related Disorders
Interventions
Propranolol, Amantadine, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 60 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 7, 2026, 10:46 AM EDT
Completed Phase 4 Interventional Results available

Attenuation of Corticosteroid Induced Hippocampal Changes

NCT01656187
View directory record Official record
Conditions
Organic Memory Impairment
Interventions
Memantine 10 mg capsule, Memantine-matched Placebo capsule
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 29, 2019 · Synced Oct 7, 2026, 10:46 AM EDT